The identification of resistance mechanisms to third‐generation tyrosine kinase inhibitors—in particular osimertinib—should be considered as a cornerstone for understanding treatment individualization in an era of precision medicine, potentially improving patient outcomes significantly through a multifactorial strategy.

中文翻译：

---

在非小细胞肺癌中克服对奥西替尼的耐药性：希望，疑惑和中间。

对第三代酪氨酸激酶抑制剂（特别是奥西替尼）的耐药机制的确定，应被视为了解精密医学时代的个体化治疗的基石，并可能通过多因素策略显着改善患者的预后。